ID   SC6A3_RAT               Reviewed;         619 AA.
AC   P23977;
DT   01-MAR-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-1992, sequence version 1.
DT   29-MAY-2024, entry version 171.
DE   RecName: Full=Sodium-dependent dopamine transporter;
DE            Short=DA transporter;
DE            Short=DAT;
DE   AltName: Full=Solute carrier family 6 member 3;
GN   Name=Slc6a3;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TRANSPORTER ACTIVITY,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND ACTIVITY REGULATION.
RX   PubMed=1948035; DOI=10.1126/science.1948035;
RA   Kilty J.E., Lorang D., Amara S.G.;
RT   "Cloning and expression of a cocaine-sensitive rat dopamine transporter.";
RL   Science 254:578-579(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TRANSPORTER ACTIVITY,
RP   BIOPHYSICOCHEMICAL PROPERTIES, ACTIVITY REGULATION, AND TISSUE SPECIFICITY.
RX   PubMed=1948034; DOI=10.1126/science.1948034;
RA   Shimada S., Kitayama S., Lin C.-L., Patel A., Nanthakumar E., Gregor P.,
RA   Kuhar M., Uhl G.;
RT   "Cloning and expression of a cocaine-sensitive dopamine transporter
RT   complementary DNA.";
RL   Science 254:576-578(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TRANSPORTER ACTIVITY,
RP   BIOPHYSICOCHEMICAL PROPERTIES, ACTIVITY REGULATION, AND TISSUE SPECIFICITY.
RX   PubMed=1765147; DOI=10.1016/0014-5793(91)81406-x;
RA   Giros B., el Mestikawy S., Bertrand L., Caron M.G.;
RT   "Cloning and functional characterization of a cocaine-sensitive dopamine
RT   transporter.";
RL   FEBS Lett. 295:149-154(1991).
RN   [4]
RP   MUTAGENESIS OF ASP-79; SER-356; SER-359; SER-403 AND SER-404, FUNCTION,
RP   TRANSPORTER ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND ACTIVITY
RP   REGULATION.
RX   PubMed=1502198; DOI=10.1073/pnas.89.16.7782;
RA   Kitayama S., Shimada S., Xu H., Markham L., Donovan D.M., Uhl G.;
RT   "Dopamine transporter site-directed mutations differentially alter
RT   substrate transport and cocaine binding.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:7782-7785(1992).
RN   [5]
RP   FUNCTION, TRANSPORTER ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=8125921; DOI=10.1016/s0021-9258(17)37256-3;
RA   Gu H., Wall S.C., Rudnick G.;
RT   "Stable expression of biogenic amine transporters reveals differences in
RT   inhibitor sensitivity, kinetics, and ion dependence.";
RL   J. Biol. Chem. 269:7124-7130(1994).
RN   [6]
RP   SUBCELLULAR LOCATION.
RX   PubMed=32963038; DOI=10.1194/jlr.ra120001087;
RA   Kuge H., Miyamoto I., Yagyu K.I., Honke K.;
RT   "PLRP2 selectively localizes synaptic membrane proteins via acyl-chain
RT   remodeling of phospholipids.";
RL   J. Lipid Res. 61:1747-1763(2020).
CC   -!- FUNCTION: Mediates sodium- and chloride-dependent transport of dopamine
CC       (PubMed:1502198, PubMed:1765147, PubMed:1948034, PubMed:1948035,
CC       PubMed:8125921). Also mediates sodium- and chloride-dependent transport
CC       of norepinephrine (also known as noradrenaline) (PubMed:8125921).
CC       Regulator of light-dependent retinal hyaloid vessel regression,
CC       downstream of OPN5 signaling (By similarity).
CC       {ECO:0000250|UniProtKB:Q61327, ECO:0000269|PubMed:1502198,
CC       ECO:0000269|PubMed:1765147, ECO:0000269|PubMed:1948034,
CC       ECO:0000269|PubMed:1948035, ECO:0000269|PubMed:8125921}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=chloride(out) + dopamine(out) + Na(+)(out) = chloride(in) +
CC         dopamine(in) + Na(+)(in); Xref=Rhea:RHEA:70919, ChEBI:CHEBI:17996,
CC         ChEBI:CHEBI:29101, ChEBI:CHEBI:59905;
CC         Evidence={ECO:0000269|PubMed:1502198, ECO:0000269|PubMed:1765147,
CC         ECO:0000269|PubMed:1948034, ECO:0000269|PubMed:1948035};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(R)-noradrenaline(out) + chloride(out) + Na(+)(out) = (R)-
CC         noradrenaline(in) + chloride(in) + Na(+)(in); Xref=Rhea:RHEA:70923,
CC         ChEBI:CHEBI:17996, ChEBI:CHEBI:29101, ChEBI:CHEBI:72587;
CC         Evidence={ECO:0000269|PubMed:8125921};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=chloride(out) + dopamine(out) + 2 Na(+)(out) = chloride(in) +
CC         dopamine(in) + 2 Na(+)(in); Xref=Rhea:RHEA:70931, ChEBI:CHEBI:17996,
CC         ChEBI:CHEBI:29101, ChEBI:CHEBI:59905;
CC         Evidence={ECO:0000269|PubMed:8125921};
CC   -!- ACTIVITY REGULATION: Inhibited by mazindol, cocaine, desipramine, GBR
CC       12783 dihydrochloride, GBR 12909 dihydrochloride and nomifensine.
CC       {ECO:0000269|PubMed:1502198, ECO:0000269|PubMed:1765147,
CC       ECO:0000269|PubMed:1948034, ECO:0000269|PubMed:1948035}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=17 uM for noradrenaline {ECO:0000269|PubMed:8125921};
CC         KM=5.2 uM for dopamine {ECO:0000269|PubMed:8125921};
CC         KM=885 nM for dopamine {ECO:0000269|PubMed:1948035};
CC         KM=1.19 uM for dopamine {ECO:0000269|PubMed:1948034};
CC         KM=300 nM for dopamine {ECO:0000269|PubMed:1765147};
CC         KM=1.63 uM for dopamine {ECO:0000269|PubMed:1502198};
CC         Vmax=300 pmol/min/mg enzyme for noradrenaline
CC         {ECO:0000269|PubMed:8125921};
CC         Vmax=300 pmol/min/mg enzyme for dopamine
CC         {ECO:0000269|PubMed:8125921};
CC   -!- SUBUNIT: Homooligomer; disulfide-linked (By similarity). Interacts with
CC       PRKCABP and TGFB1I1 (By similarity). Interacts (via N-terminus) with
CC       SYNGR3 (via N-terminus) (By similarity). Interacts with SLC18A2 (By
CC       similarity). Interacts with TOR1A (ATP-bound); TOR1A regulates SLC6A3
CC       subcellular location (By similarity). Interacts with alpha-
CC       synuclein/SNCA (By similarity). Interacts with SEPTIN4 (By similarity).
CC       {ECO:0000250|UniProtKB:Q01959, ECO:0000250|UniProtKB:Q61327}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:Q01959};
CC       Multi-pass membrane protein {ECO:0000255}. Cell projection, neuron
CC       projection {ECO:0000269|PubMed:32963038}. Cell projection, axon
CC       {ECO:0000250|UniProtKB:Q01959}. Note=Localizes to neurite tips in
CC       neuronal cells (PubMed:32963038). Colocalizes with SEPTIN4 at axon
CC       terminals, especially at the varicosities (By similarity).
CC       {ECO:0000250|UniProtKB:Q61327, ECO:0000269|PubMed:32963038}.
CC   -!- TISSUE SPECIFICITY: Brain (PubMed:1765147, PubMed:1948034). Expressed
CC       in the substantia nigra and ventral tegmental area, regions that
CC       contain dopaminergic cell bodies (PubMed:1765147).
CC       {ECO:0000269|PubMed:1765147, ECO:0000269|PubMed:1948034}.
CC   -!- MISCELLANEOUS: This protein is the target of psychomotor stimulants
CC       such as amphetamines or cocaine.
CC   -!- SIMILARITY: Belongs to the sodium:neurotransmitter symporter (SNF) (TC
CC       2.A.22) family. SLC6A3 subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M80233; AAA41100.1; -; mRNA.
DR   EMBL; M80570; AAA73143.1; -; mRNA.
DR   EMBL; S76145; AAB21099.1; -; mRNA.
DR   PIR; I59558; I59558.
DR   PIR; S20346; S20346.
DR   RefSeq; NP_036826.1; NM_012694.2.
DR   AlphaFoldDB; P23977; -.
DR   SMR; P23977; -.
DR   BioGRID; 247007; 5.
DR   IntAct; P23977; 3.
DR   MINT; P23977; -.
DR   STRING; 10116.ENSRNOP00000070728; -.
DR   BindingDB; P23977; -.
DR   ChEMBL; CHEMBL338; -.
DR   DrugCentral; P23977; -.
DR   GuidetoPHARMACOLOGY; 927; -.
DR   GlyCosmos; P23977; 4 sites, No reported glycans.
DR   GlyGen; P23977; 4 sites.
DR   iPTMnet; P23977; -.
DR   PhosphoSitePlus; P23977; -.
DR   SwissPalm; P23977; -.
DR   PaxDb; 10116-ENSRNOP00000047272; -.
DR   Ensembl; ENSRNOT00000040291.2; ENSRNOP00000047272.1; ENSRNOG00000017302.6.
DR   Ensembl; ENSRNOT00055004713; ENSRNOP00055003484; ENSRNOG00055003028.
DR   Ensembl; ENSRNOT00060044814; ENSRNOP00060037164; ENSRNOG00060025890.
DR   Ensembl; ENSRNOT00065031192; ENSRNOP00065024841; ENSRNOG00065018573.
DR   GeneID; 24898; -.
DR   KEGG; rno:24898; -.
DR   UCSC; RGD:3715; rat.
DR   AGR; RGD:3715; -.
DR   CTD; 6531; -.
DR   RGD; 3715; Slc6a3.
DR   eggNOG; KOG3659; Eukaryota.
DR   GeneTree; ENSGT00940000161224; -.
DR   InParanoid; P23977; -.
DR   OMA; HLTYASY; -.
DR   OrthoDB; 3084493at2759; -.
DR   PhylomeDB; P23977; -.
DR   TreeFam; TF343812; -.
DR   Reactome; R-RNO-379401; Dopamine clearance from the synaptic cleft.
DR   Reactome; R-RNO-442660; Na+/Cl- dependent neurotransmitter transporters.
DR   PRO; PR:P23977; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   Bgee; ENSRNOG00000017302; Expressed in thymus and 1 other cell type or tissue.
DR   GO; GO:0030424; C:axon; ISO:RGD.
DR   GO; GO:0043679; C:axon terminus; ISO:RGD.
DR   GO; GO:0009986; C:cell surface; ISO:RGD.
DR   GO; GO:0098691; C:dopaminergic synapse; IDA:SynGO.
DR   GO; GO:0016600; C:flotillin complex; ISO:RGD.
DR   GO; GO:0045121; C:membrane raft; ISO:RGD.
DR   GO; GO:0043005; C:neuron projection; IDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; ISO:RGD.
DR   GO; GO:0032809; C:neuronal cell body membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045211; C:postsynaptic membrane; IDA:SynGO.
DR   GO; GO:0042734; C:presynaptic membrane; IDA:SynGO.
DR   GO; GO:0043176; F:amine binding; IDA:RGD.
DR   GO; GO:0035240; F:dopamine binding; ISO:RGD.
DR   GO; GO:0005330; F:dopamine:sodium symporter activity; IDA:UniProtKB.
DR   GO; GO:1901363; F:heterocyclic compound binding; IPI:RGD.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008504; F:monoamine transmembrane transporter activity; ISO:RGD.
DR   GO; GO:0005326; F:neurotransmitter transmembrane transporter activity; ISO:RGD.
DR   GO; GO:0005334; F:norepinephrine:sodium symporter activity; IDA:UniProtKB.
DR   GO; GO:0002020; F:protease binding; IPI:RGD.
DR   GO; GO:0051721; F:protein phosphatase 2A binding; IPI:RGD.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:RGD.
DR   GO; GO:0005102; F:signaling receptor binding; IPI:RGD.
DR   GO; GO:0021984; P:adenohypophysis development; ISO:RGD.
DR   GO; GO:0006865; P:amino acid transport; IBA:GO_Central.
DR   GO; GO:0050890; P:cognition; ISO:RGD.
DR   GO; GO:0042416; P:dopamine biosynthetic process; ISO:RGD.
DR   GO; GO:0042420; P:dopamine catabolic process; ISO:RGD.
DR   GO; GO:0015872; P:dopamine transport; IDA:RGD.
DR   GO; GO:0090494; P:dopamine uptake; ISO:RGD.
DR   GO; GO:0051583; P:dopamine uptake involved in synaptic transmission; IBA:GO_Central.
DR   GO; GO:1990384; P:hyaloid vascular plexus regression; ISS:UniProtKB.
DR   GO; GO:0007595; P:lactation; ISO:RGD.
DR   GO; GO:0007626; P:locomotory behavior; ISO:RGD.
DR   GO; GO:0015844; P:monoamine transport; ISO:RGD.
DR   GO; GO:0006836; P:neurotransmitter transport; ISO:RGD.
DR   GO; GO:0001504; P:neurotransmitter uptake; ISO:RGD.
DR   GO; GO:0015874; P:norepinephrine transport; IBA:GO_Central.
DR   GO; GO:0040018; P:positive regulation of multicellular organism growth; ISO:RGD.
DR   GO; GO:0060134; P:prepulse inhibition; ISO:RGD.
DR   GO; GO:0042053; P:regulation of dopamine metabolic process; ISO:RGD.
DR   GO; GO:0051591; P:response to cAMP; IDA:RGD.
DR   GO; GO:0042220; P:response to cocaine; ISO:RGD.
DR   GO; GO:0045471; P:response to ethanol; IDA:RGD.
DR   GO; GO:0010039; P:response to iron ion; IEP:RGD.
DR   GO; GO:0035094; P:response to nicotine; IEP:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEP:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEP:RGD.
DR   GO; GO:0007608; P:sensory perception of smell; ISO:RGD.
DR   GO; GO:0035725; P:sodium ion transmembrane transport; IBA:GO_Central.
DR   CDD; cd11514; SLC6sbd_DAT1; 1.
DR   InterPro; IPR000175; Na/ntran_symport.
DR   InterPro; IPR002436; Na/ntran_symport_dopamine.
DR   InterPro; IPR037272; SNS_sf.
DR   NCBIfam; NF037979; Na_transp; 1.
DR   PANTHER; PTHR11616:SF38; SODIUM-DEPENDENT DOPAMINE TRANSPORTER; 1.
DR   PANTHER; PTHR11616; SODIUM/CHLORIDE DEPENDENT TRANSPORTER; 1.
DR   Pfam; PF00209; SNF; 1.
DR   PRINTS; PR01202; DOPTRANSPORT.
DR   PRINTS; PR00176; NANEUSMPORT.
DR   SUPFAM; SSF161070; SNF-like; 1.
DR   PROSITE; PS00610; NA_NEUROTRAN_SYMP_1; 1.
DR   PROSITE; PS00754; NA_NEUROTRAN_SYMP_2; 1.
DR   PROSITE; PS50267; NA_NEUROTRAN_SYMP_3; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Cell projection; Disulfide bond; Glycoprotein; Membrane;
KW   Metal-binding; Neurotransmitter transport; Reference proteome; Sodium;
KW   Symport; Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..619
FT                   /note="Sodium-dependent dopamine transporter"
FT                   /id="PRO_0000214754"
FT   TOPO_DOM        1..68
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        69..89
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        96..116
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        140..160
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        161..236
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        237..255
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        264..281
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        317..334
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        346..367
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        400..419
FT                   /note="Helical; Name=8"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        446..464
FT                   /note="Helical; Name=9"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        480..500
FT                   /note="Helical; Name=10"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        521..540
FT                   /note="Helical; Name=11"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        559..577
FT                   /note="Helical; Name=12"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        578..619
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          560..589
FT                   /note="Interaction with TGFB1I1"
FT                   /evidence="ECO:0000250"
FT   BINDING         75
FT                   /ligand="Na(+)"
FT                   /ligand_id="ChEBI:CHEBI:29101"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:Q7K4Y6"
FT   BINDING         77
FT                   /ligand="Na(+)"
FT                   /ligand_id="ChEBI:CHEBI:29101"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:Q7K4Y6"
FT   BINDING         78
FT                   /ligand="Na(+)"
FT                   /ligand_id="ChEBI:CHEBI:29101"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:Q7K4Y6"
FT   BINDING         82
FT                   /ligand="Na(+)"
FT                   /ligand_id="ChEBI:CHEBI:29101"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:Q7K4Y6"
FT   BINDING         320
FT                   /ligand="Na(+)"
FT                   /ligand_id="ChEBI:CHEBI:29101"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:Q7K4Y6"
FT   BINDING         352
FT                   /ligand="Na(+)"
FT                   /ligand_id="ChEBI:CHEBI:29101"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:Q7K4Y6"
FT   BINDING         417
FT                   /ligand="Na(+)"
FT                   /ligand_id="ChEBI:CHEBI:29101"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:Q7K4Y6"
FT   BINDING         420
FT                   /ligand="Na(+)"
FT                   /ligand_id="ChEBI:CHEBI:29101"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:Q7K4Y6"
FT   BINDING         421
FT                   /ligand="Na(+)"
FT                   /ligand_id="ChEBI:CHEBI:29101"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:Q7K4Y6"
FT   SITE            105
FT                   /note="Contributes to high-affinity binding to cocaine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61327"
FT   CARBOHYD        181
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        188
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        196
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        204
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        180..189
FT                   /evidence="ECO:0000250|UniProtKB:Q7K4Y6"
FT   DISULFID        305
FT                   /note="Interchain"
FT                   /evidence="ECO:0000250|UniProtKB:Q01959"
FT   MUTAGEN         79
FT                   /note="D->A,G,E: Significant loss of dopamine transport
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:1502198"
FT   MUTAGEN         356
FT                   /note="S->A: Reduced dopamine transport activity; when
FT                   associated with A-359."
FT                   /evidence="ECO:0000269|PubMed:1502198"
FT   MUTAGEN         356
FT                   /note="S->G: Reduced dopamine transport activity; when
FT                   associated with G-359."
FT                   /evidence="ECO:0000269|PubMed:1502198"
FT   MUTAGEN         359
FT                   /note="S->A: Reduced dopamine transport activity; when
FT                   associated with A-356."
FT                   /evidence="ECO:0000269|PubMed:1502198"
FT   MUTAGEN         359
FT                   /note="S->G: Reduced dopamine transport activity; when
FT                   associated with G-356."
FT                   /evidence="ECO:0000269|PubMed:1502198"
FT   MUTAGEN         403
FT                   /note="S->A: No effect on dopamine transport activity; when
FT                   associated with G-404."
FT                   /evidence="ECO:0000269|PubMed:1502198"
FT   MUTAGEN         404
FT                   /note="S->A: No effect on dopamine transport activity; when
FT                   associated with G-403."
FT                   /evidence="ECO:0000269|PubMed:1502198"
FT   CONFLICT        597
FT                   /note="E -> K (in Ref. 3; AAB21099)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   619 AA;  68746 MW;  DF3A30C981095D24 CRC64;
     MSKSKCSVGP MSSVVAPAKE SNAVGPREVE LILVKEQNGV QLTNSTLINP PQTPVEAQER
     ETWSKKIDFL LSVIGFAVDL ANVWRFPYLC YKNGGGAFLV PYLLFMVIAG MPLFYMELAL
     GQFNREGAAG VWKICPVLKG VGFTVILISF YVGFFYNVII AWALHYFFSS FTMDLPWIHC
     NNTWNSPNCS DAHASNSSDG LGLNDTFGTT PAAEYFERGV LHLHQSRGID DLGPPRWQLT
     ACLVLVIVLL YFSLWKGVKT SGKVVWITAT MPYVVLTALL LRGVTLPGAM DGIRAYLSVD
     FYRLCEASVW IDAATQVCFS LGVGFGVLIA FSSYNKFTNN CYRDAIITTS INSLTSFSSG
     FVVFSFLGYM AQKHNVPIRD VATDGPGLIF IIYPEAIATL PLSSAWAAVF FLMLLTLGID
     SAMGGMESVI TGLVDEFQLL HRHRELFTLG IVLATFLLSL FCVTNGGIYV FTLLDHFAAG
     TSILFGVLIE AIGVAWFYGV QQFSDDIKQM TGQRPNLYWR LCWKLVSPCF LLYVVVVSIV
     TFRPPHYGAY IFPDWANALG WIIATSSMAM VPIYATYKFC SLPGSFREKL AYAITPEKDH
     QLVDRGEVRQ FTLRHWLLL
//
